ANI PHARMACEUTICALS, INC Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
ANI PHARMACEUTICALS, INC (ANIP) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $8.46 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2026-08-07
- 2026-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $8.46M.
- 2026-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $8.57M.
- 2025-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $8.35M.
- 2025-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $7.96M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2026-06-30 | $8.46M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $8.57M 10-Q · filed 2026-08-07 |
| 2025-12-31 | $8.35M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $7.96M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $12.57M 10-Q · filed 2026-08-07 |
| 2025-03-31 | $11.65M 10-Q · filed 2026-08-07 |
| 2024-12-31 | $10.85M 10-Q · filed 2026-08-07 |
| 2024-09-30 | $12.76M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $11.93M 10-Q · filed 2025-11-07 |
| 2024-03-31 | $11.57M 10-Q · filed 2025-08-08 |
| 2023-12-31 | $23.98M 10-K · filed 2026-02-27 |
| 2023-09-30 | $34.50M 10-Q · filed 2024-11-08 |
| 2023-06-30 | $37.05M 10-Q · filed 2024-11-08 |
| 2023-03-31 | $36.02M 10-Q · filed 2024-08-06 |
| 2022-12-31 | $35.06M 10-K · filed 2025-02-28 |
| 2022-09-30 | $33.43M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $30.96M 10-Q · filed 2023-11-08 |
| 2022-03-31 | $32.05M 10-Q · filed 2023-08-09 |
| 2021-12-31 | $31.00M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |